Insights - Valeant Pharmaceuticals (VRX) agreed to raise their outstanding offer for Salix Pharmaceuticals (SLXP) to $173/share in cash, from a $158 bid announced on January 16th, after Endo International … Continue Reading
Read nowRecap - No one has the exact answer, but Mr. King’s post-JP Morgan musings from earlier this year seem relevant yet again. As of Friday’s close, the S&P 500 is actually down year-to-date, while the biotechnology sector is up an impressive 14%, as measured by the IBB. The two have clearly diverged, and it almost seems that investors are fleeing to biotechnology for safety. That’s quite a departure from years past.
Read nowInsights - Trevena, Inc. (TRVN) announced on Monday plans to upsize the phase IIb BLAST-AHF trial, testing TRV027 in acute heart failure (AHF), and to focus on the middle dose being tested in the study. The trial will be expanded from 500 to 620 patients and will weight enrolled patients towards what Trevena characterizes as the most promising dose, 5mg/hr, plus standard heart failure therapy versus placebo plus standard of care.
Read nowInsights - Orexigen Therapeutics (OREX) surged early this week with the release of positive interim study results for Contrave, the company’s approved weight loss drug. Public comments from an FDA official on Thursday evening, however, put a damper on the celebration.
Read nowInsights - Intra-Cellular Therapies, Inc. (ITCI) announced a public offering of 4.25 million shares of its common stock on Wednesday morning, prescient in light of the stock’s … Continue Reading
Read now
